XML 85 R72.htm IDEA: XBRL DOCUMENT v3.25.2
Segments of Business - Schedule of Segment Information (Details)
$ in Millions
 3 Months Ended
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment revenues    
Total revenues $ 97,827 $ 79,283
Other segment expense, net    
Total other segment expense, net 96,534 78,021
Segment operating profit    
Total operating profit (loss) 1,293 1,262
Interest expense (49) (75)
Income before income taxes 1,051 1,084
Segment depreciation and amortization    
Total segment depreciation and amortization 157 169
Segment expenditures for long-lived assets    
Total segment expenditures for long-lived assets $ 189 167
Number of reportable segments | segment 4  
Provision for bad debts $ 196 15
Credits related to LIFO accounting (7) (2)
Gains (losses) associated with equity investments 0 110
Restructuring charges 47 10
U.S. Pharmaceutical    
Segment expenditures for long-lived assets    
Provision for bad debts 189  
Operating Segments | U.S. Pharmaceutical    
Segment revenues    
Total revenues 89,954 71,715
Other segment expense, net    
Total other segment expense, net 89,227 70,934
Segment operating profit    
Total operating profit (loss) 727 781
Segment depreciation and amortization    
Total segment depreciation and amortization 63 60
Segment expenditures for long-lived assets    
Total segment expenditures for long-lived assets $ 73 $ 28
Revenue derived from services, percentage (less than) 1.00% 1.00%
Net cash proceeds from settlements $ 8 $ 90
Credits related to LIFO accounting (7) (2)
Income (loss) from equity method investments   (43)
Restructuring charges 1 1
Operating Segments | U.S. Pharmaceutical | National Prescription Opioid Litigation    
Segment expenditures for long-lived assets    
Pre-tax expenses related to estimated litigation liability   57
Operating Segments | Prescription Technology Solutions    
Segment revenues    
Total revenues 1,434 1,241
Other segment expense, net    
Total other segment expense, net 1,181 1,038
Segment operating profit    
Total operating profit (loss) 253 203
Segment depreciation and amortization    
Total segment depreciation and amortization 21 21
Segment expenditures for long-lived assets    
Total segment expenditures for long-lived assets $ 1 $ 4
Revenue derived from services, percentage (less than) 38.00% 38.00%
Restructuring charges $ 0 $ 4
Operating Segments | Medical-Surgical Solutions    
Segment revenues    
Total revenues 2,701 2,636
Other segment expense, net    
Total other segment expense, net 2,480 2,448
Segment operating profit    
Total operating profit (loss) 221 188
Segment depreciation and amortization    
Total segment depreciation and amortization 22 23
Segment expenditures for long-lived assets    
Total segment expenditures for long-lived assets $ 25 $ 51
Revenue derived from services, percentage (less than) 1.00% 1.00%
Restructuring charges $ 17 $ 3
Operating Segments | International    
Segment revenues    
Total revenues 3,738 3,691
Other segment expense, net    
Total other segment expense, net 3,646 3,601
Segment operating profit    
Total operating profit (loss) 92 90
Segment depreciation and amortization    
Total segment depreciation and amortization 14 30
Segment expenditures for long-lived assets    
Total segment expenditures for long-lived assets $ 13 $ 25
Revenue derived from services, percentage (less than) 1.00% 1.00%
Restructuring charges $ 0 $ 1
Corporate    
Segment operating profit    
Corporate expenses, net (193) (103)
Interest expense (49) (75)
Segment depreciation and amortization    
Total segment depreciation and amortization 37 35
Segment expenditures for long-lived assets    
Total segment expenditures for long-lived assets $ 77 59
Number of reportable segments | segment 3  
Gains (losses) associated with equity investments   110
Restructuring charges $ 29 1
Corporate | National Prescription Opioid Litigation    
Segment expenditures for long-lived assets    
Pre-tax expenses related to estimated litigation liability   $ 55